Brainsway Provides $6 Million Milestone-Based Convertible Loan to Neurolief

MT Newswires Live
03/26

BrainsWay (BWAY) said Thursday it has completed an additional $6 million milestone-based convertible loan to Neurolief.

The second tranche investment was triggered after the US Food and Drug Administration granted premarket approval for Neurolief's Proliv Rx system, the company said.

BrainsWay said it has invested a total of $11 million in Neurolief to date.

Under the strategic investment agreement, the company may provide additional funding, including a third tranche of up to $5 million in equity upon Neurolief reaching a specified revenue target, it added.

BrainsWay holds a call option to acquire all outstanding equity interests in Neurolief, the company said.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10